Search clinical trials for: Placebo (semaglutide)

Total 53687 results

Novo Nordisk A/S

Active, not recruiting

A Research Study Investigating Semaglutide in People With Early Alzheimer's Disease (EVOKE)

Early Alzheimer's Disease

Canada, United States, Spain, Netherlands, United Kingdom, Austria, Korea, Republic of, Portugal, Italy, Australia, Argentina, Hungary, Germany, Brazil, Poland, Denmark, Czechia, Ireland, Norway, Japan, Romania, South Africa, Sweden, ... and more
Novo Nordisk A/S

Completed

Research Study Investigating How Well Semaglutide Works in People With Type 2 Diabetes Suffering From Overweight or Obesity (STEP 2)

Obesity | Overweight

United States, India, Japan, Russian Federation, United Kingdom, Canada, Spain, South Africa, Germany, Greece, United Arab Emirates, Argentina, Puerto Rico
Novo Nordisk A/S

Completed

Research Study to Investigate How Well Semaglutide Works in People Living With Heart Failure and Obesity (STEP-HFpEF)

Obesity

United States, Israel, United Kingdom, Denmark, Germany, Netherlands, Canada, Argentina, Czechia, Hungary, Poland, Spain, Australia
Novo Nordisk A/S

Completed

Research Study of How Well Semaglutide Works in People Living With Overweight or Obesity (STEP 7)

Obesity | Diabetes Mellitus, Type 2 | Overweight

Korea, Republic of, Hong Kong, Brazil, China
Novo Nordisk A/S

Completed

Research Study to Look at How Well Semaglutide is at Lowering Weight When Taken Together With an Intensive Lifestyle Program (STEP 3)

Obesity | Overweight

United States
Woman's
Novo Nordisk A/S

Recruiting

Treatment to Regress to Normoglycemia in Women With a Recent History of GDM (SWEET)

Pre Diabetes | Postpartum Disorder

United States
Novo Nordisk A/S

Completed

Two-year Research Study Investigating How Well Semaglutide Works in People Suffering From Overweight or Obesity (STEP 5)

Obesity | Overweight

United States, Italy, Spain, Canada, Hungary
Novo Nordisk A/S

Completed

STEP 6: Research Study Investigating How Well Semaglutide Works in People Living With Overweight or Obesity (STEP 6)

Obesity | Overweight

Japan, Korea, Republic of
Novo Nordisk A/S

Completed

STEP 1: Research Study Investigating How Well Semaglutide Works in People Suffering From Overweight or Obesity (STEP 1)

Overweight or Obesity | Metabolism and Nutrition Disorder

United States, India, Mexico, Russian Federation, United Kingdom, Canada, Denmark, Finland, Belgium, Japan, Taiwan, France, Poland, Germany, Bulgaria, Argentina, Puerto Rico
Novo Nordisk A/S

Recruiting

Research Study Looking at How Well Semaglutide Tablets Taken Once Daily Work in Chinese Adults Who Are Above a Healthy Weight Range (OASIS 3) (OASIS 3)

Obesity | Overweight

China
Novo Nordisk A/S

Completed

A Trial to Assess the Pharmacokinetics, Safety and Tolerability of Semaglutide in Healthy Chinese Subjects

Diabetes Mellitus, Type 2 | Diabetes

China
Novo Nordisk A/S

Completed

First Research Study to Look at How Two Medicines, NNC0480-0389 and Semaglutide, Work Together in Healthy People, in People With High Body Weight and in People With Diabetes

Obesity | Diabetes Mellitus, Type 2 | Overweight | Healthy Volunteers

Netherlands
Novo Nordisk A/S

Completed

Research Study to Investigate How Well Semaglutide Tablets Taken Once Daily Work in East Asian People Who Are Overweight or Living With Obesity (OASIS 2)

Overweight and Obesity

Japan, Korea, Republic of
Novo Nordisk A/S

Completed

A Research Study Looking at How 50 mg Semaglutide Daily Affects Food Intake and Emptying of the Stomach in People With Obesity

Obesity

Germany
Novo Nordisk A/S

Completed

A Research Study Looking at How Well a Combination of the Medicines Semaglutide and NNC0480-0389 Works in People With Type 2 Diabetes

Diabetes Mellitus, Type 2

United States, Japan, Hungary, Poland, Russian Federation, Bulgaria, Serbia, Greece, Denmark
Novo Nordisk A/S

Completed

A Research Study of How the Medicine NNC0480-0389 Taken With Semaglutide Works in the Body of Healthy Japanese Men

Healthy Volunteers Type 2 Diabetes

Japan
Novo Nordisk A/S

Completed

Research Study Looking at How Well Semaglutide Works in People Suffering From Obesity and Knee Osteoarthritis

Obesity

Spain, United States, France, Russian Federation, Canada, Colombia, South Africa, Norway, Denmark, Saudi Arabia, Sweden
Novo Nordisk A/S

Completed

Research Study to Look at How Well Cagrilintide Together With Semaglutide Works in People With Type 2 Diabetes

Diabetes Mellitus, Type 2

United States
University of Texas Southwestern Medical Center
University of North Carolina, Chapel Hill

Recruiting

DIALYSIS-TIR Study

Type 2 Diabetes | End Stage Renal Disease on Dialysis

United States
University Health Network, Toronto

Recruiting

Semaglutide for the Treatment of Cognitive Dysfunction in Major Depressive Disorder

Major Depressive Disorder

Canada
Novo Nordisk A/S

Completed

A Research Study to Look Into How Well Semaglutide Medicine Works at Different Doses in People With Type 2 Diabetes and Overweight

Diabetes Mellitus, Type 2

United States, Poland, Puerto Rico, Hungary, Greece
Novo Nordisk A/S

Completed

Investigation of Efficacy and Safety of Three Dose Levels of Subcutaneous Semaglutide Once Daily Versus Placebo in Subjects With Non-alcoholic Steatohepatitis.

Non-alcoholic Steatohepatitis | Hepatobiliary Disorders

United States, Russian Federation, United Kingdom, Denmark, Sweden, Netherlands, Austria, Belgium, Spain, France, Bulgaria, Canada, Australia, Greece, Japan, Finland, Puerto Rico
Novo Nordisk A/S

Completed

Efficacy and Safety of Semaglutide Once-weekly Versus Placebo as add-on to SGLT-2i in Subjects With Type 2 Diabetes Mellitus (SUSTAIN 9)

Diabetes Mellitus, Type 2 | Diabetes

United States, Russian Federation, Canada, Austria, Japan, Norway, Puerto Rico
Novo Nordisk A/S

Completed

Comparing Semaglutide Administered Subcutaneously Once Daily to Semaglutide Administered Subcutaneously Once Weekly

Healthy | Diabetes

Germany
Novo Nordisk A/S

Completed

A Trial to Assess the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Oral Semaglutide in Healthy Male Japanese and Caucasian Subjects

Healthy | Diabetes Mellitus, Type 2 | Diabetes

Japan
Novo Nordisk A/S

Completed

A Research Study on How Well Semaglutide Works in Adolescents With Overweight or Obesity

Obesity | Overweight

United States, Croatia, Russian Federation, United Kingdom, Belgium, Mexico, Austria, Ireland
University Medical Center Groningen
Novo Nordisk A/S

Enrolling by invitation

SeMaglutide and Albuminuria Reduction Trial in Obese Individuals Without Diabetes (SMART)

Obesity | Albuminuria

Netherlands, Germany, Spain, Canada
Novo Nordisk A/S

Completed

Efficacy and Safety of Oral Semaglutide Versus Placebo in Subjects With Type 2 Diabetes Mellitus Treated With Diet and Exercise Only (PIONEER 1)

Diabetes Mellitus, Type 2 | Diabetes

United States, Russian Federation, Mexico, Japan, Serbia, Turkey, Italy, Czechia, Bulgaria, Algeria, Romania
Novo Nordisk A/S

Completed

Research Study Investigating How Well Semaglutide Works in People Suffering From Overweight or Obesity (STEP 4)

Obesity | Metabolism and Nutrition Disorder

United States, Israel, Spain, Netherlands, Sweden, Switzerland, South Africa, Denmark, Portugal, Ukraine
Novo Nordisk A/S

Completed

Efficacy and Safety of Semaglutide Once-weekly Versus Placebo in Drug-naïve Subjects With Type 2 Diabetes (SUSTAIN™1)

Diabetes Mellitus, Type 2 | Diabetes

United States, United Kingdom, Mexico, Russian Federation, Japan, Canada, Italy, South Africa, Romania
Novo Nordisk A/S

Completed

A Research Study on How Semaglutide Works in People With Fatty Liver Disease and Liver Damage

Non-alcoholic Steatohepatitis

United Kingdom, Spain, United States, France, Germany
Novo Nordisk A/S

Completed

Research Study Investigating How Well Semaglutide Works in People From Thailand and South Korea Living With Obesity

Obesity

Korea, Republic of, Thailand
Novo Nordisk A/S

Completed

A Research Study Comparing a New Medicine Oral Semaglutide to Placebo in People With Type 2 Diabetes (PIONEER 11)

Diabetes Mellitus, Type 2

Taiwan, Serbia, Algeria, Hungary, China, Ukraine
University Medical Centre Ljubljana

Completed

The Effects of Semaglutide on Taste, Tongue Tissue Transcriptome, Gastric Emptying and Central Neural Response in Women With PCOS and Obesity

PCOS | Gastric Emptying | Semaglutide | Taste, Altered | Tongue Tissue Transcriptome | Central Neural Response

Slovenia
Novo Nordisk A/S

Completed

Safety, Tolerability, and Profile of Action of Drug in the Body of NN9535 in Healthy Male Japanese and Caucasian Subjects

Healthy | Diabetes

United Kingdom
San Francisco Veterans Affairs Medical Center

Suspended

Semaglutide to Reduce Atrial Fibrillation Burden

Obesity | Overweight | Atrial Fibrillation

United States
Novo Nordisk A/S

Completed

A Trial Investigating the Cardiovascular Safety of Oral Semaglutide in Subjects With Type 2 Diabetes (PIONEER 6)

Diabetes Mellitus, Type 2 | Diabetes

United States, India, Israel, Italy, Mexico, United Kingdom, Canada, Denmark, Spain, Netherlands, Malaysia, Taiwan, Germany, Poland, Turkey, Argentina, South Africa, Romania, Thailand, Algeria, Brazil
Novo Nordisk A/S

Completed

A Research Study to Look at How Semaglutide Affects Gastric Emptying in People With Obesity

Obesity | Overweight

Germany
Novo Nordisk A/S

Completed

A Trial Investigating the Effect of Oral Semaglutide Compared With Placebo on Postprandial Glucose and Triglyceride Metabolism, Energy Intake, Appetite Sensations and Gastric Emptying in Subjects With Type 2 Diabetes

Diabetes Mellitus, Type 2 | Diabetes

United Kingdom
Novo Nordisk A/S

Completed

Efficacy and Safety of Oral Semaglutide Versus Placebo in Subjects With Type 2 Diabetes and Moderate Renal Impairment (PIONEER 5)

Diabetes Mellitus, Type 2 | Diabetes

United States, Israel, Poland, Russian Federation, United Kingdom, Denmark, Finland, Sweden
Novo Nordisk A/S

Completed

A Trial to Assess the Pharmacokinetics, Pharmacodynamics, and the Safety and Tolerability of Semaglutide in Healthy Male Japanese and Caucasian Subjects

Healthy | Diabetes Mellitus, Type 2 | Diabetes

Japan
Novo Nordisk A/S

Completed

A Trial Investigating the Effects of Semaglutide on ß-cell Function in Subjects With Type 2 Diabetes

Diabetes Mellitus, Type 2 | Diabetes

Germany
Yale University
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Recruiting

GLP-1 Analogue Effects on Food Cues, Stress, Motivation for Highly Palatable Foods, and Weight

Obesity

United States
Loma Linda University
Novo Nordisk A/S

Recruiting

Latino Semaglutide Study (LSS)

Obesity | Weight Loss | Overweight or Obesity | Weight, Body | Obesity; Drug | Weight Loss Trajectory

United States
Novo Nordisk A/S

Completed

A Research Study of How Oral Semaglutide Tablets Work in Healthy People Who Are Chinese

Diabetes Mellitus, Type 2 | Healthy Volunteers

China
Universitaire Ziekenhuizen KU Leuven
Jessa Hospital; Universitair Ziekenhuis Brussel; University Hospital, Antwerp; AZ... and other collaborators

Recruiting

Semaglutide for the Treatment of Glucose Intolerance in Women With Prior Gestational Diabetes (SERENA)

Glucose Intolerance After a Recent History of Gestational Diabetes

Belgium
Novo Nordisk A/S

Completed

A Research Study of How Semaglutide Works in People With Disease Affecting the Heart and/or Blood Vessels and Type 2 Diabetes

Diabetes Mellitus, Type 2

Sweden, Austria, Denmark
Odense University Hospital

Not yet recruiting

The Effect of Oral Semaglutide on Bone Turnover in Patients With T2D: a Randomized Placebo-controlled Clinical Trial

Type 2 Diabetes | Osteopenia

Denmark
Novo Nordisk A/S

Completed

Research Study Looking at How Well Semaglutide Works in People Living With Obesity and Prediabetes (STEP 10)

Obesity

United Kingdom, Canada, Denmark, Finland, Spain
University College, London

Active, not recruiting

Semaglutide 2.4 mg in Patients With Poor Weight-loss (BARI-STEP)

Obesity | Diabetes | Metabolic Syndrome

United Kingdom

Search clinical trials for: Placebo (semaglutide)

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Djibouti

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations